Skip to content
DataLookout
Start free
Menu

INTEGRANCT07206095

Integrative Diagnosis for SCD and Other RADs

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved at least 3 years 6 months later.

See at-risk trials from Hospital Universitari Vall d'Hebron Research Institute

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from May 25, 2025 to Dec 2028 Show 8 more changesShow less
    • Enrollment increased: 200 → 350 participants
    • Eligibility criteria shortened, about 11 words
    • Primary endpoints: details revised at 1 of 1 entry
    • Trial sites reduced: 9 → 4 locations
    • Study completion pushed from May 2028 to May 2031
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description expanded, about 63 words
    • Collaborators revised (3)
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

To assess the prognostic value of LoRRca ektacytometry as biomarker providing information of SCD/RADs patients severity
Timeframe: Through study completion, an average of 2 years

Secondary (1)

To investigate the correlation between LoRRca ektacytometry parameters and SCD/RADs patients genetic and phenotypic characterization.

Arms and interventions

Genetic: Analysis of genetic modifiers

Diagnostic tests: Disease phenotyping

Sites

4 sites in 1 country